Acurx Pharmaceuticals Files 8-K on Shareholder Vote

Ticker: ACXP · Form: 8-K · Filed: Sep 19, 2025 · CIK: 1736243

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

Related Tickers: ACRX

TL;DR

ACRX filed an 8-K for a shareholder vote on Sept 16th.

AI Summary

Acurx Pharmaceuticals, Inc. filed an 8-K on September 19, 2025, reporting on a submission of matters to a vote of security holders that occurred on September 16, 2025. The filing does not contain specific details about the nature of the vote or any outcomes.

Why It Matters

This filing indicates a formal process of seeking shareholder approval for certain corporate actions, which could impact the company's strategic direction or governance.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted for a vote of security holders?

The filing does not specify the exact matters that were submitted for a vote of security holders on September 16, 2025.

When was the vote by security holders held?

The earliest event reported, which includes the submission of matters to a vote of security holders, occurred on September 16, 2025.

What is the company's principal executive office address?

The company's principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.

In which state was Acurx Pharmaceuticals, Inc. incorporated?

Acurx Pharmaceuticals, Inc. was incorporated in Delaware.

What is the filing date of this 8-K report?

This 8-K report was filed on September 19, 2025.

Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 14.3 · Accepted 2025-09-19 17:16:24

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the close of business on July 21, 2025, the record date of the special meeting of Acurx Pharmaceuticals, Inc. ("we", "us", "our" and "the Company") held on September 16, 2025 (the "Special Meeting"), there were 30,524,540 shares of common stock outstanding and entitled to vote. At the Special Meeting, the holders of 19,365,579 shares of our common stock, or approximately 63.44% of our outstanding shares of common stock, were represented in person or by proxy and, therefore, a quorum was present. At the Special Meeting, our stockholders considered three proposals, which are described briefly below and in more detail in our definitive Proxy below. Proposal 1 - Approval of Warrant Exercise Our stockholders approved, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of common stock underlying the series G-2 warrants (the "Warrants") issued pursuant to that certain warrant inducement agreement, dated June 17, 2025, entered into with the investors named therein, in an amount equal to 20% or more of our common stock outstanding before the issuance of such Warrants by the following votes: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 8,816,581 602,155 123,414 9,823,429 Proposal 2 - Approval of Authorized Share Increase Our stockholders approved, increase the aggregate number of shares of common stock authorized to be issued from 200,000,000 shares to 250,000,000 shares by the following votes: Shares Voted For Shares Voted Against Abstentions 16,476,460 2,526,119 363,000 Proposal 3 - Approval of Adjournment Our stockholders approved the adjournment of the

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Acurx Pharmaceuticals, Inc. Date: September 19, 2025 By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing